Iris Postmus1, Paul C D Johnson2, Stella Trompet3, Anton J M de Craen4, P Eline Slagboom5, James J Devlin6, Dov Shiffman7, Frank M Sacks8, Patricia M Kearney9, David J Stott10, Brendan M Buckley11, Naveed Sattar12, Ian Ford13, Rudi G J Westendorp14, J Wouter Jukema15. 1. Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; Netherlands Consortium for Healthy Ageing, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: i.postmus@lumc.nl. 2. Robertson Center for Biostatistics, University of Glasgow, United Kingdom. Electronic address: paul.johnson@glasgow.ac.uk. 3. Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; Netherlands Consortium for Healthy Ageing, PO Box 9600, 2300 RC Leiden, The Netherlands; Department of Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: s.trompet@lumc.nl. 4. Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; Netherlands Consortium for Healthy Ageing, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: craen@lumc.nl. 5. Netherlands Consortium for Healthy Ageing, PO Box 9600, 2300 RC Leiden, The Netherlands; Department of Molecular Epidemiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. Electronic address: p.slagboom@lumc.nl. 6. Celera, Alameda, CA, United States. Electronic address: james.devlin@celera.com. 7. Celera, Alameda, CA, United States. Electronic address: dov.shiffman@celera.com. 8. Department of Nutrition, Harvard School of Public Health, Boston, MA, United States; Channing Division of Network Medicine, Brigham & Women's Hospital, Boston, MA, United States. Electronic address: fsacks@hsph.harvard.edu. 9. Department of Epidemiology and Public Health, University College Cork, Ireland. Electronic address: patricia.kearney@ucc.ie. 10. Institute of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, United Kingdom. Electronic address: david.j.stott@glasgow.ac.uk. 11. Department of Pharmacology and Therapeutics, University College Cork, Ireland. Electronic address: brenbuck@ucc.ie. 12. BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow, United Kingdom. Electronic address: Naveed.sattar@glasgow.ac.uk. 13. Robertson Center for Biostatistics, University of Glasgow, United Kingdom. Electronic address: ian.ford@glasgow.ac.uk. 14. Department of Gerontology and Geriatrics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; Netherlands Consortium for Healthy Ageing, PO Box 9600, 2300 RC Leiden, The Netherlands; Leyden Academy of Vitality and Ageing, Leiden, The Netherlands. Electronic address: r.g.j.westendorp@lumc.nl. 15. Department of Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands; Durrer Center for Cardiogenetic Research, Amsterdam, The Netherlands; Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands. Electronic address: j.w.jukema@lumc.nl.
Abstract
BACKGROUND:Statin therapy is widely used in the prevention and treatment of cardiovascular events and is associated with significant risk reductions. However, there is considerable variation in response to statin therapy both in terms of LDL cholesterol reduction and clinical outcomes. It has been hypothesized that genetic variation contributes importantly to this individual drug response. METHODS AND RESULTS: We investigated the interaction between genetic variants and pravastatin or placebo therapy on the incidence of cardiovascular events by performing a genome-wide association study in the participants of the PROspective Study of Pravastatin in the Elderly at Risk for vascular disease--PHArmacogenetic study of Statins in the Elderly at risk (PROSPER/PHASE) study (n = 5244). We did not observe genome-wide significant associations with a clinically meaningful differential cardiovascular event reduction by pravastatin therapy. In addition, SNPs with p-values lower than 1 × 10(-4) were assessed for replication in a case-only analysis within two randomized placebo controlled pravastatin trials, CARE (n = 711) and WOSCOPS (n = 522). rs7102569, on chromosome 11 near the ODZ4 gene, was replicated in the CARE study (p = 0.008), however the direction of effect was opposite. This SNP was not associated in WOSCOPS. In addition, none of the SNPs replicated significantly after correcting for multiple testing. CONCLUSIONS: We could not identify genetic variation that was significantly associated at genome-wide level with a clinically meaningful differential event reduction by pravastatin treatment in a large prospective study. We therefore assume that in daily practice the use of genetic characteristics to personalize pravastatin treatment to improve prevention of cardiovascular disease will be limited.
RCT Entities:
BACKGROUND: Statin therapy is widely used in the prevention and treatment of cardiovascular events and is associated with significant risk reductions. However, there is considerable variation in response to statin therapy both in terms of LDL cholesterol reduction and clinical outcomes. It has been hypothesized that genetic variation contributes importantly to this individual drug response. METHODS AND RESULTS: We investigated the interaction between genetic variants and pravastatin or placebo therapy on the incidence of cardiovascular events by performing a genome-wide association study in the participants of the PROspective Study of Pravastatin in the Elderly at Risk for vascular disease--PHArmacogenetic study of Statins in the Elderly at risk (PROSPER/PHASE) study (n = 5244). We did not observe genome-wide significant associations with a clinically meaningful differential cardiovascular event reduction by pravastatin therapy. In addition, SNPs with p-values lower than 1 × 10(-4) were assessed for replication in a case-only analysis within two randomized placebo controlled pravastatin trials, CARE (n = 711) and WOSCOPS (n = 522). rs7102569, on chromosome 11 near the ODZ4 gene, was replicated in the CARE study (p = 0.008), however the direction of effect was opposite. This SNP was not associated in WOSCOPS. In addition, none of the SNPs replicated significantly after correcting for multiple testing. CONCLUSIONS: We could not identify genetic variation that was significantly associated at genome-wide level with a clinically meaningful differential event reduction by pravastatin treatment in a large prospective study. We therefore assume that in daily practice the use of genetic characteristics to personalize pravastatin treatment to improve prevention of cardiovascular disease will be limited.
Authors: Stella Trompet; Iris Postmus; Helen R Warren; Raymond Noordam; Roelof A J Smit; Elizabeth Theusch; Xiaohui Li; Benoit Arsenault; Daniel I Chasman; Graham A Hitman; Patricia B Munroe; Jerome I Rotter; Bruce M Psaty; Mark J Caulfield; Ron M Krauss; Adrienne L Cupples; Wouter J Jukema Journal: Front Pharmacol Date: 2022-01-05 Impact factor: 5.810